Recent progress in the study on antitumor drugs targeting hypoxia-inducible factor-1.
- Author:
Jing-Jian WANG
1
;
Jing LI
;
Mei-Yu GENG
Author Information
1. School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- Publication Type:Journal Article
- MeSH:
Amphotericin B;
pharmacology;
Animals;
Antineoplastic Agents;
pharmacology;
Echinomycin;
pharmacology;
Humans;
Hypoxia-Inducible Factor 1;
antagonists & inhibitors;
genetics;
metabolism;
Indazoles;
pharmacology;
Sirolimus;
analogs & derivatives;
pharmacology;
Topotecan;
pharmacology;
Transcription, Genetic
- From:
Acta Pharmaceutica Sinica
2008;43(6):565-569
- CountryChina
- Language:Chinese
-
Abstract:
Hypoxia-inducible factor-1 (HIF-1), as a transcription factor, plays an important role in the adaptation to hypoxic microenvironment within tumors. It can induce a series of genes transcription that participate in angiogenesis, glucose metabolism, cell proliferation, and cell migration/invasion. Thus HIF-1 not only allows cancer cells to survive in hypoxic microenvironment, but also makes the tumor more aggressive. Moreover, HIF-1 also induces tumors to acquire resistance to chemo-/radio-therapy, and is related to poor prognosis. HIF-1 emerges gradually as a potential target to develop new antitumor drugs. This paper reviews recent progress in this field.
